396 related articles for article (PubMed ID: 29271271)
1. Cost-effectiveness of grass pollen subcutaneous immunotherapy (SCIT) compared to sublingual immunotherapy (SLIT) and symptomatic treatment in Austria, Spain, and Switzerland.
Brüggenjürgen B; Reinhold T
J Med Econ; 2018 Apr; 21(4):374-381. PubMed ID: 29271271
[TBL] [Abstract][Full Text] [Related]
2. Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and cost.
Dranitsaris G; Ellis AK
J Eval Clin Pract; 2014 Jun; 20(3):225-38. PubMed ID: 24444390
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of grass pollen SCIT compared with SLIT and symptomatic treatment.
Reinhold T; Brüggenjürgen B
Allergo J Int; 2017; 26(1):7-15. PubMed ID: 28217432
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of sublingual vs subcutaneous allergen immunotherapy.
Pokladnikova J; Krcmova I; Vlcek J
Ann Allergy Asthma Immunol; 2008 May; 100(5):482-9. PubMed ID: 18517082
[TBL] [Abstract][Full Text] [Related]
5. Cost-minimization analysis of sublingual immunotherapy versus subcutaneous immunotherapy for house dust mite respiratory allergic disease in Denmark.
Rønborg S; Johnsen CR; Theilgaard S; Winther A; Hahn-Pedersen J; Andreasen JN; Olsen J
J Med Econ; 2016 Aug; 19(8):735-41. PubMed ID: 26909663
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison.
Di Bona D; Plaia A; Leto-Barone MS; La Piana S; Di Lorenzo G
J Allergy Clin Immunol; 2012 Nov; 130(5):1097-1107.e2. PubMed ID: 23021885
[TBL] [Abstract][Full Text] [Related]
7. Ultra short pre-seasonal subcutaneous immunotherapy and pre-coseasonal sublingual immunotherapy for pollen allergy: an evaluation of patient's preference in real life.
Manzotti G; Pappacoda A; Dimatteo M; Scolari C; Riario-Sforza GG; Incorvaia C
Eur Ann Allergy Clin Immunol; 2013 Aug; 45(4):138-43. PubMed ID: 24067339
[TBL] [Abstract][Full Text] [Related]
8. A non-stationary Markov model for economic evaluation of grass pollen allergoid immunotherapy.
Bilancia M; Pasculli G; Di Bona D
PLoS One; 2020; 15(5):e0232753. PubMed ID: 32407326
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Six Different Allergen Extracts for Subcutaneous Specific Immunotherapy in Children: An Open-Labelled, Prospective, Controlled Observational Trial.
Kopp MV; König IR; Friedrichs F; Umpfenbach HU; Niggemann B; Millner-Uhlemann M
Int Arch Allergy Immunol; 2019; 180(4):284-290. PubMed ID: 31665735
[TBL] [Abstract][Full Text] [Related]
10. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy.
Kiel MA; Röder E; Gerth van Wijk R; Al MJ; Hop WC; Rutten-van Mölken MP
J Allergy Clin Immunol; 2013 Aug; 132(2):353-60.e2. PubMed ID: 23651609
[TBL] [Abstract][Full Text] [Related]
11. Specific immunotherapy (SIT) in the treatment of allergic rhinitis.
Hagen A; Gorenoi V; Schönermark MP
GMS Health Technol Assess; 2010 Mar; 6():Doc01. PubMed ID: 21289874
[TBL] [Abstract][Full Text] [Related]
12. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis.
Meadows A; Kaambwa B; Novielli N; Huissoon A; Fry-Smith A; Meads C; Barton P; Dretzke J
Health Technol Assess; 2013 Jul; 17(27):vi, xi-xiv, 1-322. PubMed ID: 23827204
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of grass pollen allergen immunotherapy in adults.
Di Bona D; Bilancia M; Albanesi M; Caiaffa MF; Macchia L
Allergy; 2020 Sep; 75(9):2319-2329. PubMed ID: 32096242
[TBL] [Abstract][Full Text] [Related]
14. [Comparison study of subcutaneous immunotherapy and sublingual immunotherapy in patients with allergic rhinitis].
You SH; Qin XY; Xu C; Qiu X; Luan ZL; Jia HX; Wang HT
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 May; 30(9):689-693. PubMed ID: 29771014
[No Abstract] [Full Text] [Related]
15. Cost-effectiveness analysis of grass pollen specific immunotherapy in children with allergic rhinitis compared to the standard of care symptomatic treatment in Portugal.
Farraia M; Paciência I; Castro Mendes F; Cavaleiro Rufo J; Delgado L; Moreira A
Eur Ann Allergy Clin Immunol; 2023 Sep; 55(5):212-228. PubMed ID: 34927406
[No Abstract] [Full Text] [Related]
16. Subcutaneous Versus Sublingual Immunotherapy for Adults with Allergic Rhinitis: A Systematic Review with Meta-Analyses.
Tie K; Miller C; Zanation AM; Ebert CS
Laryngoscope; 2022 Mar; 132(3):499-508. PubMed ID: 33929726
[TBL] [Abstract][Full Text] [Related]
17. Economic aspects of sublingual immunotherapy.
Incorvaia C; Ariano R; Berto P; Ciprandi G; Leo G; Boccardo R; Scurati S; Frati F
Int J Immunopathol Pharmacol; 2009; 22(4 Suppl):27-30. PubMed ID: 19944007
[TBL] [Abstract][Full Text] [Related]
18. A Cost-Minimisation Analysis Comparing Sublingual Immunotherapy to Subcutaneous Immunotherapy for the Treatment of House Dust Mite Allergy in a Swedish Setting.
Björstad Å; Cardell LO; Hahn-Pedersen J; Svärd M
Clin Drug Investig; 2017 Jun; 37(6):541-549. PubMed ID: 28326466
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma.
Hesse L; Nawijn MC
Methods Mol Biol; 2017; 1559():137-168. PubMed ID: 28063043
[TBL] [Abstract][Full Text] [Related]
20. Sublingual or subcutaneous immunotherapy for allergic rhinitis?
Durham SR; Penagos M
J Allergy Clin Immunol; 2016 Feb; 137(2):339-349.e10. PubMed ID: 26853126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
